<DOC>
	<DOC>NCT02142218</DOC>
	<brief_summary>The purpose of this program is to provide treatment with nivolumab to subjects with Stage III or Stage IV advanced melanoma.</brief_summary>
	<brief_title>Expanded Access Program With Nivolumab to Treat Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com ECOG Performance Status of 01 Histologically confirmed malignant melanoma Progressed on or after treatment with an antiCTLA4 Active brain metastases Life Expectancy &lt;6 weeks Subjects who received prior therapy targeting Tcell costimulation or checkpoint pathways except for Anti CTLA4 therapy Subjects with autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>